Engineered Dendritic Cell Vaccine Draws Immune Cells Into Lung Tumors but Falls Short of Shrinkage
A phase I trial found that a CCL21-engineered dendritic cell vaccine combined with pembrolizumab safely increased T cell infiltration in ...
A phase I trial found that a CCL21-engineered dendritic cell vaccine combined with pembrolizumab safely increased T cell infiltration in ...
A case report describes pembrolizumab-induced myasthenia gravis with isolated anti-titin antibody positivity in a man twelve years after thymectomy for ...
A rare but serious infusion accident has been documented for the first time in the medical literature. Urologists at University ...
A new systematic review and meta-analysis finds that starting lenvatinib below 20 mg with pembrolizumab neither clearly preserves tumor response ...
A new case report describes a pembrolizumab-treated patient who developed primary hypothyroidism from immune thyroid destruction followed by rare isolated ...
A first-in-human phase I trial found that the liposomal iNKT cell agonist IMM60, given alone or with pembrolizumab, was well ...
Two patients with microsatellite-unstable metastatic colorectal cancer and markedly reduced HLA-I expression achieved durable responses to pembrolizumab, suggesting that NK ...
Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin chemotherapy maintains a durable ...
Bridging studies confirm that the Ventana MMR RxDx Panel and FoundationOne CDx reliably identify dMMR/MSI-H tumor patients likely to respond ...
A phase I trial found that the IAP antagonist tolinapant combined with pembrolizumab was well tolerated and produced a 33 ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine